Effect of immunotherapy on cerebellar ataxia with paraneoplastic cerebellar degeneration. Summary of 9 studies. (DOC 39 kb
Detection of cerebellar demyelination, axonal damage, and remyelination in MP4-immunized mice. (a) L...
Table S1. Immune Checkpoint Inhibitors (CPIs) in Patients with Cancer and Prior Solid Organ Transpla...
Table S1. Primary antibodies and working dilutions used for immunoblotting. Table S2. RNAi sequences...
Summary of 20 studies on the effects of various immunotherapies in patients with anti-GAD antibodies...
Efficacy of IVIg as induction therapy on gluten ataxia. Summary of four studies. (DOC 35 kb
Table S1. Immunomodulatory agents. Table S2. Non-immunomodulatory agents. (PDF 317 kb
Table S1. List of contributors. Table S2. Allied health professional interventions. Table S3. Pallia...
Example template of recommended content for the schedule of enrolment, interventions, and assessment...
List of DEGs characterizing SPMS untreated vs. RRMS untreated patients. (XLSX 21 kb
Table S1. Neuro-psychiatric adverse events grouping as a function of Medical Dictionary for Regulato...
Table S1. Scoring of inflammatory infiltrates. Each level of the spinal cord was examined for the nu...
Table S2. Detailed information about the antibodies used in the experiments. (DOCX 16 kb
Additional supplementary information (Figures, Tables and Materials and Methods). (DOCX 2090 kb
Table S1. Quality assessment for randomized controlled trials by Cochrane risk evaluation tool. Tabl...
Application of every criterion in the new approach in 10 paraneoplastic limbic encephalitis cases. 1...
Detection of cerebellar demyelination, axonal damage, and remyelination in MP4-immunized mice. (a) L...
Table S1. Immune Checkpoint Inhibitors (CPIs) in Patients with Cancer and Prior Solid Organ Transpla...
Table S1. Primary antibodies and working dilutions used for immunoblotting. Table S2. RNAi sequences...
Summary of 20 studies on the effects of various immunotherapies in patients with anti-GAD antibodies...
Efficacy of IVIg as induction therapy on gluten ataxia. Summary of four studies. (DOC 35 kb
Table S1. Immunomodulatory agents. Table S2. Non-immunomodulatory agents. (PDF 317 kb
Table S1. List of contributors. Table S2. Allied health professional interventions. Table S3. Pallia...
Example template of recommended content for the schedule of enrolment, interventions, and assessment...
List of DEGs characterizing SPMS untreated vs. RRMS untreated patients. (XLSX 21 kb
Table S1. Neuro-psychiatric adverse events grouping as a function of Medical Dictionary for Regulato...
Table S1. Scoring of inflammatory infiltrates. Each level of the spinal cord was examined for the nu...
Table S2. Detailed information about the antibodies used in the experiments. (DOCX 16 kb
Additional supplementary information (Figures, Tables and Materials and Methods). (DOCX 2090 kb
Table S1. Quality assessment for randomized controlled trials by Cochrane risk evaluation tool. Tabl...
Application of every criterion in the new approach in 10 paraneoplastic limbic encephalitis cases. 1...
Detection of cerebellar demyelination, axonal damage, and remyelination in MP4-immunized mice. (a) L...
Table S1. Immune Checkpoint Inhibitors (CPIs) in Patients with Cancer and Prior Solid Organ Transpla...
Table S1. Primary antibodies and working dilutions used for immunoblotting. Table S2. RNAi sequences...
DOI
Add to ORKG